[{"data":1,"prerenderedAt":258},["ShallowReactive",2],{"story-109376-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":32,"questions":33,"relatedArticles":58,"body_color":256,"card_color":257},"109376",null,"Pharmaceutical Innovation Signals Healthcare Market Consolidation | Seller Opportunity in Medical Device Distribution","- Axpaxli Phase 3 data shows 74% vision maintenance vs 56% for Eylea; $2.75B AMD market creates B2B distribution opportunities for medical supply sellers",[],[10,11,12,13,14,15,16,17,14,18,19,20,21,22,23,14,24,25,22,26,27,28,29,30,31],"https://insights.citeline.com/resizer/v2/5BFG6BW3CRK67BOR7AGW7SCZUA.jpg?smart=true&auth=c98bc221af0e1c34b5edaefce9778ff34c0b12234faeb086fa44569efbcb7a86&width=700&height=394","https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Ocular/eye-analysis.webp?t=1589292229","https://www.statnews.com/wp-content/uploads/2025/06/AdobeStock_339856159-645x645.jpeg","https://content.timothysykes.com/cdn-cgi/image/quality=90,format=webp,width=740/https://content.timothysykes.com/wp-content/uploads/2026/02/ocular-therapeutix-faces-srevenue-decline-and-investors-concerns.png","https://marketminute.ghost.io/content/images/size/w1200/2026/02/6ba55cc6-4494-472c-9483-adca94fcbed0.png","https://qtxasset.com/cdn-cgi/image/w=384,h=216,f=auto,fit=crop,g=0.5x0.5/https://qtxasset.com/quartz/qcloud5/media/image/GettyImages-2184611675.jpg?VersionId=oR9f.tGQ_F4mMb0YPCDK4e_H2Vg6h2Kb","https://static.asianetnews.com/images/w-1280,h-720,format-webp,imgid-external,imgname-image-2757eaf3-6f36-4a27-9b81-f9b159070a69.webp","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2166181809/image_2166181809.jpg?io=getty-c-w630","https://content.stockstotrade.com/wp-content/uploads/2026/02/volatile-stock-market-trends-31.png","https://d5bp8bijhhba2.cloudfront.net/image/cover_image/e234e5b2d58d9b077dd6bbb7759d33815812eebef11112eb71c557ab103d9b1e.png","https://pro.thestreet.com/.image/ar_16:9%2Cc_fill%2Ccs_srgb%2Cfl_progressive%2Cq_auto:good%2Cw_1200/MjIwNTMzMTU3NzM1MTgwMTQx/biotech.jpg","https://s.tradingview.com/static/images/illustrations/news-story.jpg","https://cdn.zonebourse.com/static/resize/1200/675//images/reuters/2024-10-09T081107Z_1_LYNXMPEK98083_RTROPTP_3_GERMANY.JPG","https://blog.tipranks.com/wp-content/uploads/2022/09/shutterstock_1549769756-750x406.jpg","https://www.nasdaq.com/sites/acquia.prod/files/2019-05/0902-Q19%20Total%20Markets%20photos%20and%20gif_CC8.jpg","https://www.manilatimes.net/manilatimes/uploads/images/2026/02/14/937808.jpg","https://medcitynews.com/wp-content/uploads/sites/7/2021/10/GettyImages-175133840.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2253559091/image_2253559091.jpg?io=getty-c-w1536","https://endpoints.news/wp-content/uploads/2025/03/eye-shutterstock-social1.jpg","https://static.biospace.com/dims4/default/1b93f13/2147483647/strip/true/crop/4801x2703+0+249/resize/1000x563!/quality/90/?url=https%3A%2F%2Fstatic.biospace.com%2F39%2F63%2F2504a1d14dbd8ea8fff4236ffe36%2Fistock-487167882.jpg","https://news.stocktwits-cdn.com/large_ocular_therapeutix_jpg_e5ff9ff87d.webp","https://cdn.sanity.io/images/0vv8moc6/ophtalmology/80beddeac1f3deb87aa582567de04cc9783729ee-1200x675.jpg?w=1200&max-h=675&fit=crop&auto=format","**Ocular Therapeutix's Axpaxli demonstrates significant clinical superiority in wet age-related macular degeneration (AMD) treatment**, with Phase 3 SOL-1 trial results showing 74.1% of patients maintaining visual acuity at week 36 compared to 55.8% receiving Regeneron's low-dose Eylea formulation. The 18.3 percentage point advantage at week 36 and 21 percentage point margin at week 52 (65.9% vs 44.2%) met the study's primary endpoint for superior durability with less frequent injections. However, the stock market reacted negatively with a 25% share decline, indicating investor expectations exceeded the clinical data—a critical lesson for sellers monitoring biotech sector dynamics and healthcare market consolidation.\n\n**For cross-border e-commerce sellers, this pharmaceutical development signals emerging opportunities in medical device distribution and healthcare supply chains.** The wet AMD market affects millions of patients globally and represents a $2.75B+ annual pharmaceutical market (Eylea alone generated $2.75B in 2025 sales for Regeneron). As Axpaxli pursues FDA approval through a new drug application with Special Protocol Assessment clarification established in 2024, the competitive pressure on Eylea creates downstream opportunities: medical supply distributors can position themselves to serve ophthalmology clinics, hospitals, and specialty pharmacies requiring injection supplies, patient education materials, and treatment tracking systems. Sellers specializing in medical packaging, cold-chain logistics, or healthcare compliance software can capitalize on the market expansion as multiple therapies compete for adoption.\n\n**The market dynamics reveal critical seller insights about expectation management and competitive positioning.** William Blair analysts noted the control arm (Eylea) outperformed expectations rather than Axpaxli underperforming—a distinction that mirrors e-commerce dynamics where positive metrics don't guarantee market success if they fall short of stakeholder expectations. The SOL-R non-inferiority trial expected to read out in early 2027 targeting a more stable patient population suggests a multi-year competitive cycle, creating sustained demand for supporting services. Sellers in medical device distribution, healthcare logistics, and compliance technology should monitor FDA approval timelines and reimbursement coverage decisions by insurance providers and government healthcare systems, as these regulatory milestones directly impact market adoption rates and create procurement opportunities for healthcare facilities preparing for new treatment options.\n\n**Strategic implications for sellers include supply chain positioning and market timing.** The narrow margin of superiority (18-22 percentage points) compared to investor expectations suggests the wet AMD market will remain competitive with multiple approved therapies coexisting—Eylea, Novartis's Beovu, and other anti-VEGF therapies. This fragmented market creates opportunities for specialized distributors, logistics providers, and compliance solution sellers to differentiate through superior service rather than competing on product alone. Sellers should monitor Ocular's FDA interactions and medical conference presentations scheduled for detailed SOL-1 results, as approval announcements will trigger procurement cycles at healthcare facilities nationwide.",[34,37,40,43,46,49,52,55],{"title":35,"answer":36,"author":5,"avatar":5,"time":5},"Why did Ocular's stock decline 25% despite positive clinical trial results?","William Blair analysts attributed the 25% stock decline to compressed effect sizes, noting the control arm (Eylea) outperformed expectations rather than Axpaxli underperforming. This indicates investor expectations for the clinical data exceeded the actual results, demonstrating that positive metrics don't guarantee market success if they fall short of stakeholder projections. The modest 18-22 percentage point superiority margin, while clinically significant, may limit commercial differentiation in a competitive market with multiple effective approved therapies. This market reaction illustrates a critical principle for sellers: managing stakeholder expectations and communicating results clearly are as important as achieving operational improvements.",{"title":38,"answer":39,"author":5,"avatar":5,"time":5},"When will Axpaxli receive FDA approval and what are the regulatory milestones?","Ocular Therapeutix plans to pursue FDA approval through a new drug application following formal agency discussions, with detailed SOL-1 results to be presented at an upcoming medical conference. The FDA and Ocular established a Special Protocol Assessment in 2024 clarifying eligible patient populations. If approved, Axpaxli would become the first tyrosine kinase inhibitor (TKI) launched for wet AMD. The company's ongoing SOL-R non-inferiority trial targeting a more stable patient population is expected to read out in early 2027. Sellers should monitor FDA approval announcements and reimbursement coverage decisions by insurance providers and government healthcare systems, as these milestones directly trigger procurement cycles at healthcare facilities.",{"title":41,"answer":42,"author":5,"avatar":5,"time":5},"How should medical supply sellers prepare for Axpaxli's potential FDA approval?","Sellers should monitor Ocular's FDA interactions, medical conference presentations, and reimbursement coverage decisions by insurance providers and government healthcare systems. Approval announcements will trigger procurement cycles at ophthalmology clinics and hospitals nationwide requiring injection supplies, cold-chain logistics, patient education materials, and treatment tracking systems. Sellers should develop relationships with specialty pharmacy networks and healthcare facility procurement departments now, positioning themselves to support the transition as new therapies enter the market. Additionally, sellers should track the SOL-R trial timeline (expected early 2027 readout) and Regeneron's competitive response with high-dose Eylea formulations, as these developments will shape long-term market dynamics and procurement patterns.",{"title":44,"answer":45,"author":5,"avatar":5,"time":5},"What is the competitive landscape for wet AMD treatments and market opportunities?","The wet AMD treatment market includes established competitors beyond Eylea, including Novartis's Beovu and other anti-VEGF therapies. Regeneron continues expanding its high-dose Eylea formulation with extended dosing intervals of 8-16 weeks, creating a multi-therapy competitive environment. This fragmented market creates sustained opportunities for medical supply distributors, logistics providers, and compliance solution sellers to serve healthcare facilities managing multiple treatment options. The competitive pressure suggests the market will remain dynamic through 2027 and beyond as Ocular's SOL-R trial results emerge. Sellers should position themselves to support healthcare facility procurement cycles triggered by new therapy approvals and reimbursement coverage decisions.",{"title":47,"answer":48,"author":5,"avatar":5,"time":5},"What are the key risks and opportunities for e-commerce sellers in the competitive wet AMD treatment market?","Key risks include pricing compression from competitive intensity between Axpaxli and Eylea, potential reimbursement delays or coverage limitations, and the possibility that Axpaxli's modest clinical advantage may not translate to significant market share gains. Opportunities include capturing demand for patient support services, complementary medical products, and logistics partnerships as treatment options expand. Sellers should diversify across multiple product categories (injection supplies, recovery products, vision aids, patient education) rather than betting on single-drug dominance. The ongoing SOL-R trial (reading out early 2027) will further shape market segmentation, so sellers should monitor regulatory developments and payer coverage decisions to optimize product positioning and inventory planning.",{"title":50,"answer":51,"author":5,"avatar":5,"time":5},"What supply chain opportunities exist in the ophthalmology medical device sector?","The ophthalmology sector requires specialized supply chains including cold-chain logistics for temperature-sensitive injectables, medical packaging compliant with FDA regulations, healthcare compliance software for treatment tracking, and specialty pharmacy distribution networks. As multiple wet AMD therapies compete for market share, healthcare facilities need reliable suppliers for injection equipment, patient education materials, and treatment documentation systems. Sellers specializing in medical device distribution, cold-chain logistics, healthcare compliance technology, or specialty pharmacy support can differentiate through superior service, regulatory expertise, and facility-specific customization. The $2.75B+ wet AMD market and ongoing competitive dynamics through 2027 create sustained demand for these supporting services.",{"title":53,"answer":54,"author":5,"avatar":5,"time":5},"How does this pharmaceutical development create opportunities for medical supply sellers?","The wet AMD market represents a $2.75B+ annual pharmaceutical market with millions of patients globally requiring ongoing treatment. As Axpaxli pursues FDA approval and competes with Eylea, Beovu, and other anti-VEGF therapies, healthcare facilities will need supporting supplies including injection equipment, patient education materials, cold-chain logistics, and treatment tracking systems. Medical device distributors, specialty pharmacy suppliers, and healthcare compliance software providers can position themselves to serve ophthalmology clinics and hospitals preparing for multiple approved treatment options. The competitive market fragmentation creates opportunities for differentiation through superior service and specialized logistics rather than product competition alone.",{"title":56,"answer":57,"author":5,"avatar":5,"time":5},"What are the clinical trial results for Ocular's Axpaxli compared to Regeneron's Eylea?","Ocular Therapeutix's Phase 3 SOL-1 trial showed Axpaxli maintained visual acuity in 74.1% of patients at week 36 versus 55.8% for low-dose Eylea, representing an 18.3 percentage point advantage. At week 52, the gap widened to 65.9% versus 44.2%, a 21 percentage point difference. The study enrolled 344 newly diagnosed wet AMD patients and met its primary endpoint of superiority with high statistical significance. These results demonstrate Axpaxli's extended durability between treatments, potentially reducing patient treatment burden through fewer clinical visits. However, the modest margin compared to investor expectations triggered a 25% stock decline, indicating market perception matters as much as clinical data.",[59,64,69,73,77,81,85,89,93,97,101,105,109,113,117,122,126,130,133,138,142,147,151,156,160,163,167,171,175,179,183,188,193,197,200,203,206,209,213,216,220,224,229,233,236,239,242,246,249,253],{"id":60,"title":61,"source":62,"logo":31,"time":63},436436,"Ocular Therapeutix releases positive topline results from SOL-1","https://www.ophthalmologytimes.com/view/ocular-therapeutix-releases-positive-topline-results-from-sol-1","1D AGO",{"id":65,"title":66,"source":67,"logo":5,"time":68},437404,"Ocular Therapeutix selloff brings attractive entry point, says Citizens","https://www.tipranks.com/news/the-fly/ocular-therapeutix-selloff-brings-attractive-entry-point-says-citizens-thefly-news","20H AGO",{"id":70,"title":71,"source":72,"logo":23,"time":63},436437,"Ocular Therapeutix: SOL-1 Data Validate Axpaxli and Overdone Sell-Off Supports Buy Rating","https://www.tipranks.com/news/ratings/ocular-therapeutix-sol-1-data-validate-axpaxli-and-overdone-sell-off-supports-buy-rating-ratings-news",{"id":74,"title":75,"source":76,"logo":16,"time":63},436438,"OCUL Stock Surges Overnight Ahead Of Crucial Wet AMD Data Readout, Sanofi Takeover Buzz Builds","https://newsable.asianetnews.com/markets/ocul-stock-surges-overnight-ahead-of-crucial-wet-amd-data-readout-sanofi-takeover-buzz-builds-articleshow-h7srx43",{"id":78,"title":79,"source":80,"logo":20,"time":63},436439,"Promising Biotech Ocular Gets Price Target Update After Groundbreaking Therapy News","https://pro.thestreet.com/trade-ideas/promising-biotech-ocular-gets-price-target-update-after-groundbreaking-therapy-news",{"id":82,"title":83,"source":84,"logo":5,"time":63},436443,"Ocular Therapeutix (OCUL) Drops 22% Despite Positive Trial Resul","https://www.gurufocus.com/news/8623150/ocular-therapeutix-ocul-drops-22-despite-positive-trial-results",{"id":86,"title":87,"source":88,"logo":24,"time":63},436444,"Ocular Therapeutix's AXPAXLI Meets Superiority Endpoint In Wet AMD Trial, But Stock Down","https://www.nasdaq.com/articles/ocular-therapeutixs-axpaxli-meets-superiority-endpoint-wet-amd-trial-stock-down",{"id":90,"title":91,"source":92,"logo":29,"time":63},436445,"Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA","https://www.biospace.com/drug-development/oculars-hydrogel-beats-regenerons-eylea-in-wet-amd-study-plots-path-to-fda",{"id":94,"title":95,"source":96,"logo":5,"time":63},436446,"Ocular Therapeutix’s wet AMD treatment shows superiority over aflibercept","https://www.investing.com/news/company-news/ocular-therapeutixs-wet-amd-treatment-shows-superiority-over-aflibercept-93CH-4508389",{"id":98,"title":99,"source":100,"logo":18,"time":63},436440,"Ocular Therapeutix Financial Results Disappoint Investors","https://stockstotrade.com/news/ocular-therapeutix-inc-ocul-news-2026_02_17/",{"id":102,"title":103,"source":104,"logo":19,"time":63},436441,"Ocular Therapeutix Shares Drop Following Axpaxli Trial Data Disappointment","https://intellectia.ai/news/stock/ocular-therapeutix-shares-drop-following-axpaxli-trial-data-disappointment",{"id":106,"title":107,"source":108,"logo":13,"time":63},436442,"Ocular Therapeutix Struggles After Missing Revenue Expectations","https://www.timothysykes.com/news/ocular-therapeutix-inc-ocul-news-2026_02_17/",{"id":110,"title":111,"source":112,"logo":5,"time":68},436429,"Ocular Therapeutix Shares Fall After Eye Disease Treatment Shows Superiority in Phase 3 Trial at Week 36","https://www.marketscreener.com/news/ocular-therapeutix-shares-fall-after-eye-disease-treatment-shows-superiority-in-phase-3-trial-at-wee-ce7e5dd9dd81f62c",{"id":114,"title":115,"source":116,"logo":21,"time":63},436425,"OCUL: AXPAXLI demonstrated statistically significant superiority to aflibercept in wet AMD at Week 52","https://www.tradingview.com/news/urn:summary_document_report:quartr.com:2855978:0-ocul-axpaxli-demonstrated-statistically-significant-superiority-to-aflibercept-in-wet-amd-at-week-52/",{"id":118,"title":119,"source":120,"logo":5,"time":121},436426,"Ocular Therapeutix Shares Jump 28% as SOL-1 Nears Key Data","https://www.gurufocus.com/news/8621629/ocular-therapeutix-shares-jump-28-as-sol1-nears-key-data","17H AGO",{"id":123,"title":124,"source":125,"logo":10,"time":121},436427,"Ocular Says Phase III Data Show Hydrogel Axitinib Could Reset Wet AMD Treatment","https://insights.citeline.com/scrip/business/strategy/ocular-says-phase-iii-data-show-hydrogel-axitinib-could-reset-wet-amd-treatment-R2KNW6STXFAR3H64I4UABUQPQQ/",{"id":127,"title":128,"source":129,"logo":26,"time":68},436428,"Ocular Therapeutix Eyes FDA Filing After Wet AMD Drug Tops Regeneron’s Eylea in Phase 3 Test","https://medcitynews.com/2026/02/ocular-therapeutix-wet-age-related-macular-degeneration-amd-axpaxli-tki-ocul/",{"id":131,"title":75,"source":132,"logo":5,"time":63},436432,"https://menafn.com/1110749409/OCUL-Stock-Surges-Overnight-Ahead-Of-Crucial-Wet-AMD-Data-Readout-Sanofi-Takeover-Buzz-Builds",{"id":134,"title":135,"source":136,"logo":11,"time":137},438335,"Eylea threatened Inlyta Ocular’s phase III win with Axpaxli?","https://www.bioworld.com/articles/728992-eylea-threatened-inlyta-oculars-phase-iii-win-with-axpaxli","23H AGO",{"id":139,"title":140,"source":141,"logo":5,"time":137},436433,"Ocular eyes superiority claim after Axpaxli success in wet AMD study, but shares fall","https://firstwordpharma.com/story/7106721",{"id":143,"title":144,"source":145,"logo":22,"time":146},438336,"Ocular Therapeutix to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026","https://www.marketscreener.com/news/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesda-ce7e5dd8d98aff27","2D AGO",{"id":148,"title":149,"source":150,"logo":5,"time":137},436434,"Ocular claims a win with eye drug data even as shares sink","https://www.biopharmadive.com/news/ocular-therapeutix-succeeded-phase-3-eye-drug-data-axpaxli-eylea/812329/",{"id":152,"title":153,"source":154,"logo":5,"time":155},437402,"Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron's Eylea","https://www.msn.com/en-us/health/other/ocular-therapeutix-plunges-as-modest-benefit-overshadow-trial-win-over-regenerons-eylea/ar-AA1Wxcyk","14H AGO",{"id":157,"title":158,"source":159,"logo":5,"time":63},436435,"Ocular Therapeutix (OCUL) Stock Drops Following SOL-1 Trial Results","https://www.gurufocus.com/news/8623954/ocular-therapeutix-ocul-stock-drops-following-sol1-trial-results",{"id":161,"title":95,"source":162,"logo":5,"time":63},437403,"https://uk.investing.com/news/company-news/ocular-therapeutixs-wet-amd-treatment-shows-superiority-over-aflibercept-93CH-4509898",{"id":164,"title":165,"source":166,"logo":5,"time":63},438459,"Ocular Therapeutix stock news: Why positive data led to a 25% drop","https://finance.yahoo.com/news/ocular-therapeutix-stock-news-why-133034174.html",{"id":168,"title":169,"source":170,"logo":5,"time":63},438331,"Ocular Therapeutix stock tumbles after wet AMD trial results By Investing.com","https://uk.investing.com/news/stock-market-news/ocular-therapeutix-stock-tumbles-after-wet-amd-trial-results-93CH-4509908",{"id":172,"title":173,"source":174,"logo":28,"time":63},438332,"Ocular Therapeutix’ Axpaxli shows superiority over Eylea, shares sink","https://endpoints.news/ocular-therapeutixs-axpaxli-could-become-first-choice-in-wet-amd-after-showing-superiority-over-eylea/",{"id":176,"title":177,"source":178,"logo":5,"time":68},436430,"Ocular Therapeutix (OCUL) Shares Drop Amid Clinical Study Results","https://www.gurufocus.com/news/8624432/ocular-therapeutix-ocul-shares-drop-amid-clinical-study-results",{"id":180,"title":119,"source":181,"logo":5,"time":182},438333,"https://www.tradingview.com/news/gurufocus:535e90091094b:0-ocular-therapeutix-shares-jump-28-as-sol-1-nears-key-data/","18H AGO",{"id":184,"title":185,"source":186,"logo":27,"time":187},436431,"Ocular: \"Buy\" As AXPAXLI Program For Wet-AMD Moves To Potential NDA Filing (NASDAQ:OCUL)","https://seekingalpha.com/article/4871002-ocular-buy-as-axpaxli-program-for-wet-amd-moves-to-potential-nda-filing","21H AGO",{"id":189,"title":190,"source":191,"logo":5,"time":192},438334,"Ocular Therapeutix™ Reports Positive Results from Landmark SOL-1 Phase 3 Superiority Trial in Wet AMD","https://markets.businessinsider.com/news/stocks/ocular-therapeutix-reports-positive-results-from-landmark-sol-1-phase-3-superiority-trial-in-wet-amd-1035834687","19H AGO",{"id":194,"title":195,"source":196,"logo":5,"time":63},436421,"Ocular Therapeutix announces SOL-1 Phase 3 of Axpaxli met primary endpoint","https://www.tipranks.com/news/the-fly/ocular-therapeutix-announces-sol-1-phase-3-of-axpaxli-met-primary-endpoint-thefly-news",{"id":198,"title":169,"source":199,"logo":5,"time":63},436422,"https://ca.investing.com/news/stock-market-news/ocular-therapeutix-stock-tumbles-after-wet-amd-trial-results-93CH-4461440",{"id":201,"title":169,"source":202,"logo":5,"time":63},436423,"https://in.investing.com/news/stock-market-news/ocular-therapeutix-stock-tumbles-after-wet-amd-trial-results-93CH-5242516",{"id":204,"title":153,"source":205,"logo":22,"time":63},436424,"https://www.marketscreener.com/news/ocular-therapeutix-s-eye-drug-superior-to-regeneron-s-eylea-in-late-stage-trial-ce7e5dd8d18ef127",{"id":207,"title":165,"source":208,"logo":5,"time":63},436447,"https://ca.investing.com/news/stock-market-news/ocular-therapeutix-stock-news-why-positive-data-led-to-a-25-drop-4461671",{"id":210,"title":211,"source":212,"logo":5,"time":63},436448,"Ocular Therapeutix (OCUL) Achieves Success in Phase 3 Trial for Wet AMD Treatment","https://www.gurufocus.com/news/8621813/ocular-therapeutix-ocul-achieves-success-in-phase-3-trial-for-wet-amd-treatment",{"id":214,"title":165,"source":215,"logo":5,"time":63},436449,"https://www.investing.com/news/stock-market-news/ocular-therapeutix-stock-news-why-positive-data-led-to-a-25-drop-4508627",{"id":217,"title":218,"source":219,"logo":12,"time":63},436493,"Ocular’s experimental eye drug beats low dose of Regeneron’s Eylea in late-stage trial","https://www.statnews.com/2026/02/17/ocular-therapeutix-axpaxli-wet-amd-treatment-compared-to-eylea-regeneron/",{"id":221,"title":222,"source":223,"logo":14,"time":63},436454,"Retina’s ‘Sustained’ Moment: Ocular Therapeutix Braces for Game-Changing Phase 3 AXPAXLI Data","http://markets.chroniclejournal.com/chroniclejournal/article/marketminute-2026-2-16-retinas-sustained-moment-ocular-therapeutix-braces-for-game-changing-phase-3-axpaxli-data",{"id":225,"title":226,"source":227,"logo":25,"time":228},436455,"Ocular Therapeutix™ to Announce Topline Data for SOL-1 Phase 3 Superiority Trial in Wet AMD on Tuesday, February 17, 2026","https://www.manilatimes.net/2026/02/14/tmt-newswire/globenewswire/ocular-therapeutix-to-announce-topline-data-for-sol-1-phase-3-superiority-trial-in-wet-amd-on-tuesday-february-17-2026/2278293","4D AGO",{"id":230,"title":231,"source":232,"logo":5,"time":228},436456,"Ocular Therapeutix to Host Webcast Presenting SOL-1 Data for AXPAXLI™ on February 17, 2026","https://www.quiverquant.com/news/Ocular+Therapeutix+to+Host+Webcast+Presenting+SOL-1+Data+for+AXPAXLI%E2%84%A2+on+February+17%2C+2026",{"id":234,"title":165,"source":235,"logo":5,"time":63},436450,"https://uk.investing.com/news/stock-market-news/ocular-therapeutix-stock-news-why-positive-data-led-to-a-25-drop-4510136",{"id":237,"title":190,"source":238,"logo":5,"time":63},436494,"https://finance.yahoo.com/news/ocular-therapeutix-reports-positive-results-120000412.html",{"id":240,"title":75,"source":241,"logo":30,"time":63},436451,"https://stocktwits.com/news-articles/markets/equity/ocul-stock-surges-overnight-ahead-of-wet-amd-data-readout-sanofi-takeover-buzz/cZRW370R4MS",{"id":243,"title":244,"source":245,"logo":15,"time":137},436495,"Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Eylea, but investors balk","https://www.fiercepharma.com/pharma/ocular-therapeutix-eyes-path-wet-amd-dominance-ph-3-win-over-regenerons-leading-eylea",{"id":247,"title":222,"source":248,"logo":14,"time":63},436452,"https://markets.financialcontent.com/wral/article/marketminute-2026-2-16-retinas-sustained-moment-ocular-therapeutix-braces-for-game-changing-phase-3-axpaxli-data",{"id":250,"title":251,"source":252,"logo":17,"time":63},436496,"Ocular drops after late-stage trial data for wet AMD therapy","https://seekingalpha.com/news/4552486-ocular-drops-after-trial-data-wet-amd-drug",{"id":254,"title":222,"source":255,"logo":14,"time":63},436453,"https://markets.financialcontent.com/stocks/article/marketminute-2026-2-16-retinas-sustained-moment-ocular-therapeutix-braces-for-game-changing-phase-3-axpaxli-data","#8b804bff","#8b804b4d",1771450264597]